The COO's $260K open-market sale at $7.50 is a notable bearish signal from a C-suite insider, especially given no apparent 10b5-1 plan. The director's $25K buy is too small to offset. Monitor for additional insider sales or a material event (e.g., clinical data, partnership) that may have prompted the sale. The stock's 78% analyst bullishness and strong institutional accumulation (4 doubled positions) provide a counterweight, watch for divergence between insider and institutional behavior.
PGEN drugs
PGEN drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 26 $7.42entry
- T+1 · 3mo ago −3.10%α −3.75% · $7.19
- T+5 · 3mo ago −5.53%α −5.41% · $7.01
- T+20 · 8w ago +3.77%α +3.55% · $7.70
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Precigen insiders show a mixed cluster: Director Nancy Agee made a small $25K open-market buy, while COO Rutul Shah sold $260K worth of shares at $7.50. The sell is 10x the buy in dollar terms and comes from a C-suite executive, creating a bearish tilt. At $2.6B market cap, the total $285K in trades is only ~0.01% of market cap, trivial in scale, but the insider weighting (C-suite sell vs. director buy) and the fact that the sell was an open-market transaction (not a tax-withholding or plan sale) warrant attention.
Key Financial Metrics
Key Facts
- COO Rutul Shah sold 34,700 shares at $7.50 for $260K in an open-market sale.
- Director Nancy Agee bought 3,400 shares at $7.23 for $25K in an open-market purchase.
- Total cluster value is $285K, representing ~0.01% of $2.6B market cap.
- The sell is from a C-suite insider and is 10x larger than the buy in dollar terms.
- No 10b5-1 plan or regular pattern is evident in the sell, it appears discretionary.
Financial Impact
$260K insider sale by COO vs. $25K insider buy by director; net insider outflow of $235K.
Risk Factors
- COO's sale may signal negative non-public information about pipeline or commercial progress.
- Further insider selling could accelerate if the stock remains near $7.50.
- Director buy is small and may be a routine portfolio rebalance, not a conviction signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PGEN-1787727934461 |
Track record
13 reports on PGEN
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +52.17% at T+60 after the May 13, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
- Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
- Aug 25, 202611w ago Insider Cluster Bearish 4/10 Viewing Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
- Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
- Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
- Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers